Transient IFNγ-STAT1 inhibition prevents TI signatures and splenic infection resistance.
(A) Experimental schema of training with early treatment of Fedratinib inhibitor. (B) Splenic S.Tm CFU for control and BCG mice, with and without Fedratinib inhibitor, 24h post infection (n=2-6).(C) MP populations from control (gray) and BCG (black) mice, with or without Fedratinib inhibition. Percentage of CM and NCM cells calculated from CD11b+ population. Percentage of RPM calculated from Lin- population. (D) Percentage of CM, NCM, and RPM populations expressing CXCL9 from control (gray) and BCG (black) mice, with or without Fedratinib inhibition (control: n=3, BCG: n=4, control+Fedratinib: n=3, BCG+Fedratinib: n=6). (E) Heatmap of normalized log2 expression of DEGs across naïve and training conditions. (F) Gene set enrichment analysis of DEGs from E. Data in bar graphs are presented as mean±SEM. For bar graph B each individual point is a biological repeat. Heatmap rows in E indicate biological replicates. Two-tailed t-test used for data in B, C, and D (*P<0.05, **P<0.01, ***P<0.005, ****P<0.001).